(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
21 Incredibly Entertaining Contemplations To Observe Consistently - 2Munich Security Conference chief defends inviting AfD lawmakers
- 3IAF intercepts over 90% of drones launched by Iran, Hezbollah during Operation Roaring Lion
- 435 million tons of food go to waste yearly in the US. Experts share tips to help stop it
- 5Shooting of MIT professor Nuno Loureiro has police searching for a suspect
- People Are Sharing The One Picture They Can't See Without Laughing, And It's The Comedy Spiral You Need Today
- Hubble Space Telescope spies dusty debris from two cosmic collisions
- Building an Individual Brand: Illustrations from Forces to be reckoned with
- Old food pyramid vs. RFK Jr.'s new food pyramid. See what's different.
- Flu cases are spiking earlier than usual. What you need to know.
- Shredded cheese recall: Multiple brands sold at Aldi, Target and Walmart affected over potential metal fragment contamination
- Can humans have babies in space? It may be harder than expected
- Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
